In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1855 News Items found
Doctor in green surgical scrubs wearing glasses and cap looking at camera.
Q&A
Q & A: MSK Leads the Way in Treating Head and Neck Cancers

Learn how MSK specialists treat head and neck cancers using the most innovative approaches.
Image of liver with tumors
In the Clinic
Pumped Up: Implanted Chemotherapy Device Improves Survival when Colorectal Cancer Spreads to the Liver

A retrospective study from MSK has found that colorectal cancer patients with liver metastases live an average of two years longer when they receive an additional treatment called hepatic arterial infusion (HAI).
James Eastham, Chief of the Urology Service at Memorial Sloan Kettering
In the Clinic
MSK Expert Explains New Prostate Cancer Screening Guideline

MSK surgeon James Eastham explains the pros and cons of PSA testing and weighs in on a new US Preventive Services Task Force guideline.
photo of blood vials
Finding
Blood Will Tell: Scientists Find Clues to Immunotherapy Responders and Non-Responders

Why do some patients respond to immunotherapy while others do not? Blood may hold the answer.
MSK Researchers Study Blood Biomarkers to Help Answer Questions about Why Some Patients Don't Respond to Immunotherapy

Researchers from Memorial Sloan Kettering Cancer Center (MSK) and their colleagues at the University of Pennsylvania (UPenn), in collaboration with the Parker Institute for Cancer Immunotherapy (PICI), studied changes in the blood of patients with stage IV melanoma who were all treated with the PD-1 drug pembrolizumab. Researchers looked at circulating immune cells called T cells that showed signs of being “reinvigorated” by the PD-1 therapy. For more information or to arrange interviews please e-mail Rebecca Williams at [email protected].
Physician standing in front of a whiteboard
Finding
Novel Drug Advancing to Phase II Basket Trial of Solid Tumors

Learn more about entrectinib, a targeted therapy being evaluated in patients with solid tumors.
Grey T lymphocytes
Finding
#AACR17: Researchers Shed Light on Biological Activity of a New, First-in-Class Immunotherapy

A team at MSK uncovered how TRX518, a new immunotherapy drug in early development, works in the body.
immune cells
Finding
#AACR17: Study Explores Best Time to Give CAR T Cell Therapy

Leukemia patients may do better on CAR T cell therapy when they are treated early, before their disease relapses.
Finding
New Data Show Some Patients with Melanoma Live Longer When Receiving Immunotherapy Combination

For some patients with metastatic melanoma, a combination of two immunotherapies works better than either drug alone.
David Hyman and Robin Gillespie
Finding
#AACR17: Basket Trial for Experimental Drug Shows Promising Early Results

Neratinib, which targets mutations that drive cancer growth, is showing promise for treating several types of cancer.